Phenotypes Associated with This Genotype

Genotype
MGI:3850443

• Allelic Composition: Nf2^tm2Gth/Nf2^tm2Gth; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:132943 )

• following adenoviral cre treatment, median survival time is 135 days

neoplasm

increased tumor incidence ( J:132943 )

• following adenoviral cre treatment, 86% of mice develop thoracic tumors (including malignant mesotheliomas, 45 of 55; rhabdomyosarcomas, 2 of 55; and schwannomas, 1 of 55)

• following adenoviral cre treatment, mice develop either non-aggressive epitheloid or mixed tumors with confined invasion of the visceral pleural or (sarcomatoid) tumors with strong invasion of visceral and parietal pleura

• following adenoviral cre treatment, 4% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus

• following adenoviral cre treatment, 11% of mice develop aspecific tumors not induced by adeno-cre treatment

• following adenoviral cre treatment, latency to developing malignant mesotheliomas is lower than in mice carrying other combinations of Cdkn2a^tm2Brn, Nf2^tm2Gth, and Trp53^tm1Brn alleles

increased T cell derived lymphoma incidence ( J:132943 )

• a few following adenoviral cre treatment

increased uterus leiomyoma incidence ( J:132943 )

♀ • in 7% of mice following adenoviral cre treatment

increased rhabdomyosarcoma incidence ( J:132943 )

increased leukemia incidence ( J:132943 )

• following adenoviral cre treatment, 7% mice develop monocytic myeloid leukemias

increased mesothelioma incidence ( J:132943 )

• following adenoviral cre treatment, latency to developing malignant mesotheliomas is lower than in mice carrying other combinations of Cdkn2a^tm2Brn, Nf2^tm2Gth, and Trp53^tm1Brn alleles

increased Schwannoma incidence ( J:132943 )

liver/biliary system

enlarged liver ( J:132943 )

• following adenoviral cre treatment, 4% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus

muscle

increased uterus leiomyoma incidence ( J:132943 )

♀ • in 7% of mice following adenoviral cre treatment

increased rhabdomyosarcoma incidence ( J:132943 )

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:132943 )

• a few following adenoviral cre treatment

growth/size/body

enlarged liver ( J:132943 )

• following adenoviral cre treatment, 4% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus

reproductive system

increased uterus leiomyoma incidence ( J:132943 )

♀ • in 7% of mice following adenoviral cre treatment

nervous system

increased Schwannoma incidence ( J:132943 )

immune system

increased T cell derived lymphoma incidence ( J:132943 )

• a few following adenoviral cre treatment

hematopoietic system

increased T cell derived lymphoma incidence ( J:132943 )

• a few following adenoviral cre treatment

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
malignant mesothelioma		DOID:1790	OMIM:156240	J:132943